ESMO 2018
European Society for Medical Oncology Congress
Interviews and expert commentary from ESMO 2018 — study authors and key opinion leaders discuss the findings and their clinical implications.
Head and Neck Cancer Therapy De-Escalation: A “Salutary Lesson”
MUNICH—A “salutary lesson” was reported by researchers investigating therapy for oropharyngeal cancer at the 2018 annual congress of the European Society for Medical Oncology (ESMO). It ca
Which New Combination for Metastatic Renal Cell Cancer?
MUNICH—A leading European oncologist acknowledged the impressive life-extending potential of new drug combinations for metastatic renal cell carcinoma discussed at the 2018 annual congress of the Euro
Two Drug Combination Doubled Kidney Cancer Progression Free Survival
MUNICH— A doubling of progression free survival (PFS) and objective response rate (ORR) was observed in patients who had their previously untreated advanced renal cell cancer (RCC) treated with a comb
ALK—Targeted Lung Cancer Drugs Benefited Real World Patients
MUNICH— Anaplastic lymphoma kinase (ALK) inhibitors are as effective in “real world” clinical use for treating patients with non-small cell lung cancer (NSCLC) who test positive for ALK ge
First Line PARP Inhibition For Ovarian Cancer Assessed
MUNICH—The role of poly ADP ribose polymerase (PARP) inhibitors for treating newly diagnosed advanced ovarian cancer was under review at the 2018 annual congress of the European Society for Medical On
BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib
BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib MUNICH—An “unprecedented improvement” in progression free survival (PFS) was observed in the randomized controlled
PD-L1 Immunotherapy Delayed Triple Negative Breast Cancer Progression
MUNICH— Immunotherapy with the anti programmed death ligand 1 (PD-L1) checkpoint inhibitor atezolizumab in combination with nab-paclitaxel chemotherapy prolonged progression-free survival (PFS) among
Genomically Targeted Therapy Delays Advanced Breast Cancer Progression
MUNICH—A combination of the phosphoinositide 3-kinase (PI3K) inhibitor alpelisib plus fulvestrant significantly extended progression free survival (PFS) compared to placebo plus fulvestr
Palbociclib Combination Prolongs Life After Breast Cancer Hormone Therapy
MUNICH—Patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer who were treated with a combination of the cyclin dependent kina
Long Overall Survival in Ceritinib-Treated ALK-Positive Lung Cancer
MUNICH—More than four years median overall survival was reported in patients treated with an inhibitor of anaplastic lymphoma kinase (ALK) for their ALK gene rearranged non-small cell lung cancer (NSC
Cabozantinib Improved Hepatocellular Carcinoma Survival Beyond Sorafenib
BARCELONA—Oral cabozantinib “significantly improved” overall survival (OS) and progression free survival (PFS) compared to placebo in patients with advanced hepatocellular carcinoma(HCC) w